Clinical trial
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To…
NCT00264615 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00264615 |
|---|---|
| Title | Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa |
| Official title | An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug |
| Interventions | lamotrigine extended-release |
| Enrollment | 45 |
| Start date | Oct 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Dec 13, 2005 |
| Last update posted | Sep 23, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: